In univariate analysis, larger tumour size, with pharmaceutical drug adjuvant therapy, high FNCLCC grade, increased COL11A1, ITGA10 and KIF26B expression, and decreased CLEC3B, DUOX2, KRT75 and PPP2R2B were risk factors of shorter RFS (Table 1). Here, DUOX2 is linked to neoplasm.